

# CERTIFICATE

Survey of 30 May 2025

You have fulfilled the requirements of the External Quality Assessment with the following analysis

## Molecular Genetics 27 - BRCA1 BRCA2 (779):

Validity 24 months:

BRCA1 mutation type (R: B5)

BRCA2 mutation type (R: B5)

(R) analysis is subject to the RiliBÄK

Customer:  
10041629  
Medyczne Laboratoria Diagnostyczne  
INVICTA Sp. z o.o.  
Polna 64  
81-740 Sopot

Düsseldorf, 25 June 2025



Prof. Dr. med. Michael Spannagl  
(Head of Reference Institution)



Dr. rer. nat. Morten O. Christensen  
(Adviser)

# CERTIFICATE OF PARTICIPATION

Survey of 30 May 2025

You have participated in the External Quality Assessment with the following analysis

## Molecular Genetics 27 - BRCA1 BRCA2 (779):

BRCA1 mutation type (R: B5)

BRCA2 mutation type (R: B5)

(R) analysis is subject to the RiliBÄK

Customer:  
10041629  
Medyczne Laboratoria Diagnostyczne  
INVICTA Sp. z o.o.  
Polna 64  
81-740 Sopot

Düsseldorf, 25 June 2025



Prof. Dr. med. Michael Spannagl  
(Head of Reference Institution)



Dr. rer. nat. Morten O. Christensen  
(Adviser)